DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

GlaxoSmithKline (NYSE: GSK)

company name or ticker
Company Photos
(Click to zoom)

Isis Pharmaceuticals Inc. Strikes Out on Its Own

Isis Pharmaceuticals uses its third-quarter earnings call to announce a reorganization as it pushes into late-stage development on its own.

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig

Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.

Why Sarepta Therapeutics Inc. Stock Imploded in October

Sarepta Therapeutics was one of the worst biotech stocks in October. Find out why its shares lost nearly one-quarter of their value and whether or not they're poised for a rebound.

PRGO, GSK And MYL, 3 Drugs Stocks Pushing The Industry Lower

Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog

Noteworthy ETF Inflows: VGK, GSK, BTI, RDS.B

Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October

ISIS Pharmaceuticals was among October's top performing biotech stocks. Find out why ISIS catapulted higher by 19%, as well as whether or not this run can continue.

GlaxoSmithKline PLC (GSK) Ex-Dividend Date Scheduled for November 05, 2014

Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog

Arena Pharmaceuticals, Inc. Earnings: Looking for More

A prescription growth rate of 30% sounds good, but Belviq has such low sales, it's hard to get too excited yet. If phase 3 trials pan out, long-term growth will likely come from use as a smoking cessation drug and as a combination product for obesity.